SCHEMBL2938007

SCHEMBL2938007

COc1ccc(CNC(=O)c2cc(CN3CC(=O)N(c4ccc(OC(F)(F)F)cc4)C3=O)ccn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
RAB9A P51151 2/20 0.43
MMP13 P45452 1/20 0.43
HPGD P15428 5/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2C9 P11712 3/20 0.41
CYP2C19 P33261 3/20 0.41
IGF1R P08069 2/20 0.41
EPHX2 P34913 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
CYP2D6 P10635 2/20 0.41
ADRB2 P07550 1/20 0.41
KDM4E B2RXH2 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934045 0.92 CYP2C9 (0.42) ALDH1A1SMN1; SMN2MMP13HPGDCYP1A2
SCHEMBL2934266 0.90 IGF1R (0.54) ALDH1A1SMN1; SMN2RAB9AMMP13IGF1R
SCHEMBL2936936 0.89 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2RAB9AMMP13HPGD
SCHEMBL2933018 0.87 IGF1R (0.50) ALDH1A1SMN1; SMN2IGF1REPHX2PPARD
SCHEMBL2939230 0.84 GCGR (0.52) ALDH1A1RAB9AMMP13HPGDCYP1A2
SCHEMBL2936043 0.84 MMP13 (0.45) ALDH1A1RAB9AMMP13IGF1REPHX2
SCHEMBL2941004 0.84 IGF1R (0.60) RAB9AIGF1R
SCHEMBL2938008 0.84 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2IGF1REPHX2PPARD
SCHEMBL2934887 0.84 IGF1R (0.47) ALDH1A1SMN1; SMN2IGF1RPPARDPPARA
SCHEMBL2935376 0.84 PPARD (0.48) ALDH1A1SMN1; SMN2IGF1REPHX2PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 ALDH1A1 3413/4885SMN1; SMN2 3761/4885RAB9A 1706/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA ALDH1A1 2827/4885SMN1; SMN2 4365/4885RAB9A 2275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.